MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo

NCT04389099 | Completed

• 1 other identifier: PSS2018/MAPLE-BERTHOLDT/SKJ
• Study Type: observational
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

Introduction: The placenta is the organ that permits the maternal-fetal exchange of the oxygen and nutrients. The development of its vascular network occurs in the first trimester. Any deficit during this important angiogenesis procedure can lead to the dysfunction of the placental vasculature, which can potentially cause pathologies including preeclampsia (PE) and intrauterine growth restriction (IUGR). PE concerns 3% of the pregnancy in France. It can occur at any gestational age and leads to serious complications such as eclampsia, the HELLP syndrome or the retro-placental hematoma. IUGR does not only lead to the morbidity and fetal and neonatal mortality, but also has a predisposition for certain pathologies in the adulthood. Many groups have studied the placenta vasculature at the microscopic (histological) scale. However, recent studies show that in addition to the damage at the microvasculature level, the macroscopic placental vessel architecture is also altered. Nonetheless, the origin and the etiology of this phenomenon remains unknown. Since it is difficult to apply in-vivo imaging techniques on pregnant women due to the restriction of usage of contrast agent. Alternatively, ex-vivo MR angiography (MRA) techniques have been developed by our team and others to visualize the entire placental vasculature in a faster way (as compared to corrosion casting). Up to now, only the study of the healthy placenta is done and published. The analysis of the pathological placental vasculature (i.e. PE and IUGR cases) at different gestational age and its comparison to the physiological ones have not been conducted, which will potentially enable a better understanding of the placental vasculature pathology. Objectives: the main objective of this study is to compare the vasculature architecture of the normal and pathological placentas (with possible alteration in the placental vasculature). Methods and analysis: This is a monocentric, prospective, controlled but not randomized study. The investigators expect to include 110 women in Nancy. The pregnant women will be recruited when they arrived at the maternity hospital for delivery, for both the physiological and potential pathological cases. The notice of this study will be given. If no opposition is given by the subject, the placenta may be collected. This study will not collect the patient consent but only the opposition declaration will be collected.

Conditions

Pre-Eclampsia; Fetal Growth Retardation

Outcome Measures

Primary Outcomes (5)

• Placental vasculature architecture indice: total vascular density

  through study completion, on average of 24 months

• Placental vasculature architecture indice: placental artery density (cm3)

  through study completion, on average of 24 months

• Placental vasculature architecture indice: placental vien density (cm3)

  through study completion, on average of 24 months

• Placental vasculature architecture indice: placental vessel tortuosity

  through study completion, on average of 24 months

• Placental vasculature architecture indice: placental vessel tree branching

  through study completion, on average of 24 months

Study Arms (2)

Healthy placenta (control)

Pregnant women without preeclampsia and/or fetal growth restriction

Pathological placenta

Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia with or without fetal growth restriction ; fetal growth restriction without preeclampsia.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* healthy placenta group: 50 inclusion (among which, 10 is to establish the final technical protocol) * pathological placenta group: 60 (30 preeclampsia and 30 intrauterine restricted growth only cases)

You may qualify if:

• already received the complete information about the study and do not express any opposition to the utilisation of their data
• mandatory enrolment in a social security plan
• gestational age more than 30 weeks (and until at term)
• patient with either natural delivery or with cesarean section and whose placenta is naturally completely separated (directed delivery only)

You may not qualify if:

• younger than 18 years old
• new borns with congenital disease (either suspected at birth or already diagnosed)
• presence of only one umbilical artery
• presence of a maternal pathology: gestational or pre-existing diabetes, autoimmune diseases that may have an impact on placental vascularization (Antiphospholipid Antibody Syndrome, Immune Thrombocytopenia, Myasthenia, Systemic Lupus Erythematosus), cancer,
• do not speak the French language, or inability to understand the given information of the study
• manual delivery
• incomplete placenta
• placenta with true marginal insertions (cord insertion within 1 cm of the placental margin) and/or velaments of the cord
• Person referred to Articles L.1121-6 and L-1121-8 of the Public Health Code

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Centre Hospitalier Régional Universitaire de Nancy

Vandœuvre-lès-Nancy, 54500, France

Location

Related Publications (1)

• Dap M, Chen B, Banasiak C, Hossu G, Morel O, Beaumont M, Bertholdt C. Magnetic Resonance Imaging Angiography of Physiological and Pathological Pregnancy Placentas Ex Vivo: Protocol for a Prospective Pilot Study. JMIR Res Protoc. 2022 Aug 10;11(8):e35051. doi: 10.2196/35051.

  PMID: 35947435 DERIVED

MeSH Terms

Conditions

Pre-Eclampsia; Fetal Growth Retardation

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Fetal Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Growth Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Charline BERTHOLDT

  Central Hospital, Nancy, France

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator (gynecologist-obstetrician)

Study Record Dates

• First Submitted: May 6, 2020
• First Posted: May 15, 2020
• Study Start: November 18, 2019
• Primary Completion: November 17, 2024
• Study Completion: November 17, 2024
• Last Updated: February 13, 2025

Record last verified: 2024-02

Locations

FR (1)